According to the report, one driver in market is growing prevalence of diabetes in the world.
In 2015, approximately 415 m people in the world had diabetes, which is expected to increase to around 642 m by 2040.
As of 2015, it has been estimated that 9.1% adults in the world have diabetes and this is expected to increase to 10% by 2040.
In addition, 75%-80% of the individuals with diabetes belonged to low- and middle-income countries. The number of people with diabetes is high in APAC.
According to OECD, the prevalent cases are going to reach about 47,973,000 in Europe, 66,812,000 in the Americas, and 18,234,000 in Africa by 2030. The global prevalence of diabetes was estimated to be 9% among adults aged above 18 years.
Key players in this market include Abbott Laboratories, Roche Diagnostics, LifeScan and Medtronic.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults